Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodie... Checkpoint Therapeutics Inc is an immuno-oncology biopharmaceutical company based in the US. It focuses on the acquisition, development, and commercialization of novel, non-chemotherapy, immune-enhanced combination treatments for patients with solid tumor cancers. Its licensed portfolio of antibodies includes targeting programmed cell death-ligand 1 (PD-L1), glucocorticoid-induced TNFR related protein (GITR) and carbonic anhydrase IX (CAIX). It emphasizes on developing novel immuno-oncology and checkpoint inhibitor antibodies as well as oral targeted anti-cancer therapies consisting of an inhibitor of epidermal growth factor receptor (EGFR) mutations, an inhibitor of the bromodomain and extra-terminal (BET) protein, BRD4, and an inhibitor of poly (ADP-ribose) polymerase (PARP). Show more
PDUFA goal date of November 4, 2024 for DFD-29 for the treatment of inflammatory lesions and erythema of rosacea in adults FDA accepted Biologics License Application resubmission for cosibelimab...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.215 | 9.7065462754 | 2.215 | 2.58 | 2.17 | 454828 | 2.41989985 | CS |
4 | 0.15 | 6.57894736842 | 2.28 | 2.58 | 2.06 | 316422 | 2.29244598 | CS |
12 | 0.43 | 21.5 | 2 | 2.81 | 2 | 382511 | 2.35088982 | CS |
26 | 0.51 | 26.5625 | 1.92 | 2.81 | 1.38 | 377821 | 2.05410995 | CS |
52 | 0.56 | 29.9465240642 | 1.87 | 3.62 | 1.3 | 505804 | 2.10578495 | CS |
156 | -29.47 | -92.3824451411 | 31.9 | 46.4 | 1.3 | 540726 | 13.61057875 | CS |
260 | -21.67 | -89.9170124481 | 24.1 | 53.762 | 1.3 | 632003 | 21.10161933 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.